Drug Approval | September 06, 2021
DGCI approves Hetero’s Tocilizumab
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The segment delivered strong sales growth of 20% YoY
Subscribe To Our Newsletter & Stay Updated
